UBE2V1 Antikörper (C-Term, Isoform 3)

Produktnummer ABIN357577

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch UBE2V1 in WB und EIA. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für UBE2V1 Antikörper (C-Term, Isoform 3) (ABIN357577)

Target: UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1 (UBE2V1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser UBE2V1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Produktdetails anti-UBE2V1 Antikörper

Bindungsspezifität: C-Term, Isoform 3

Spezifität: This antibody is specific to UBE2V1 (C-term, Isoform 3). Predicted to cross react with Mouse and Zebrafish (100 % Antigen Homology).

Aufreinigung: Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.

Immunogen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human UBE2V1.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: ELISA: 1/1,000. Western Blot: 1/100-1/500.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.25 mg/mL

Buffer: PBS with 0.09 % (W/V) Sodium Azide as preservative.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Details zu UBE2V1

Target: UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1 (UBE2V1))

Andere Bezeichnung: UBE2V1 / CROC1

Hintergrund: The CROC1 isoforms, also known as UBE2V1, show sequence similarity to ubiquitin-conjugating enzymes (UBCs, or E2s) but lack the conserved cysteine residue critical to catalytic activity of E2s.1 Northern blot analysis detected approximately 2.1- and 2.5-kb CROC1 transcripts in all human tissues examined, with the highest levels in brain, skeletal muscle, and kidney. Partial human intestinal epithelial cell cDNAs have been isolated containing the 3-primecoding sequence and 3-prime untranslated region of UBE2V1, also called UEV1.2 UEV1 does not have ubiquitin-conjugating activity in vitro. UEV1 transcripts are downregulated upon differentiation of a colon carcinoma cell line.1 Constitutive expression of exogenous UEV1 protein in these colon carcinoma cells inhibits their capacity to differentiate upon confluence and induces changes in cell cycle behavior associated with inhibition of CDK1. A heterodimeric protein complex has been identified that links TRAF6 to IKK activation.3 Peptide mass fingerprinting analysis revealed that this complex is composed of the ubiquitin conjugating enzyme UBC13 and the UBC-like protein UBE2V1, also called UEV1A. TRAF6, a RING domain protein, functions together with UBC13/UEV1A to catalyze the synthesis of unique polyubiquitin chains linked through lysine-63 (K63) of ubiquitin. Blockade of this polyubiquitin chain synthesis, but not inhibition of the proteasome, prevents the activation of IKK by TRAF6. These results unveil a new regulatory function for ubiquitin, in which IKK is activated through the assembly of K63-linked polyubiquitin chains.Synonyms: CROC-1, P/OKcl.19, TRAF6-regulated IKK activator 1 beta Uev1A, UBE2V, UEV-1, UEV1, Ubiquitin-conjugating enzyme E2 variant 1

Molekulargewicht: 19307 Da

Gen-ID: 387522

NCBI Accession: NP_001027459

UniProt: Q13404

Pathways: T-Zell Rezeptor Signalweg, Fc-epsilon Rezeptor Signalübertragung, Activation of Innate immune Response, Toll-Like Receptors Cascades